Biogen’s SPINRAZA High-Dose Approval Isn’t a Label Update — It’s a Lifecycle Defense Strategy in a Therapy Area That Is Running Out of Time
The FDA's approval of a high-dose nusinersen regimen looks like a routine label expansion. Read it as a commercial...